These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31432638)

  • 21. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers.
    Bast RC; Skates S; Lokshin A; Moore RG
    Int J Gynecol Cancer; 2012 May; 22 Suppl 1(Suppl 1):S5-8. PubMed ID: 22543921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women.
    Gentry-Maharaj A; Blyuss O; Ryan A; Burnell M; Karpinskyj C; Gunu R; Kalsi JK; Dawnay A; Marino IP; Manchanda R; Lu K; Yang WL; Timms JF; Parmar M; Skates SJ; Bast RC; Jacobs IJ; Zaikin A; Menon U
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Establishment and validation of a prediction model for early-stage epithelial ovarian cancer based on LASSO regression].
    Luo HJ; Wang SJ; Zhang XF; Tian WY; Luo W; Dong ZL
    Zhonghua Yi Xue Za Zhi; 2024 Jun; 104(23):2167-2172. PubMed ID: 38871475
    [No Abstract]   [Full Text] [Related]  

  • 24. Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer.
    Simmons AR; Clarke CH; Badgwell DB; Lu Z; Sokoll LJ; Lu KH; Zhang Z; Bast RC; Skates SJ
    Int J Gynecol Cancer; 2016 Jul; 26(6):1070-7. PubMed ID: 27206285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the Cutoff Point and Diagnostic Value of the Neutrophil-to-Lymphocyte Ratio in Predicting Ovarian Cancer Compared to Pathological Findings.
    Hosseini MS; Amiri F; Rezapour M; Ashraf Ganjoie T; Farzaneh F; Arab M; Talayeh M; Beheshti Rooy R; Hadi F
    Asian Pac J Cancer Prev; 2024 Mar; 25(3):971-976. PubMed ID: 38546079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BC-DETECT: combined detection of serum HE4 and TFF3 improves breast cancer diagnostic efficacy.
    Abdelrazek MA; Nageb A; Barakat LA; Abouzid A; Elbaz R
    Breast Cancer; 2022 May; 29(3):507-515. PubMed ID: 34994942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human epididymis protein 4, a novel potential biomarker for diagnostic and prognosis monitoring of lung cancer.
    Zhang T; Chu L; Tan W; Ye C; Dong H
    Clin Respir J; 2024 May; 18(5):e13774. PubMed ID: 38742362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nomogram development for predicting ovarian tumor malignancy using inflammatory biomarker and CA-125.
    Winarno GNA; Harsono AB; Suardi D; Salima S; Mantilidewi KI; Bayuaji H; Mulyantari AI; Yulianto FA; Susiarno H
    Sci Rep; 2024 Jul; 14(1):15790. PubMed ID: 38982118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
    Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
    Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. D-dimer, Fibrinogen and Tumor Marker Levels in Patients with benign and Malignant Ovarian Tumors.
    Farzaneh F; Salimnezhad M; Hosseini MS; Ashraf Ganjouee T; Arab M; Talayeh M
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4263-4268. PubMed ID: 38156862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort.
    Fortner RT; Vitonis AF; Schock H; Hüsing A; Johnson T; Fichorova RN; Fashemi T; Yamamoto HS; Tjønneland A; Hansen L; Overvad K; Boutron-Ruault MC; Kvaskoff M; Severi G; Boeing H; Trichopoulou A; Benetou V; La Vecchia C; Palli D; Sieri S; Tumino R; Matullo G; Mattiello A; Onland-Moret NC; Peeters PH; Weiderpass E; Gram IT; Jareid M; Quirós JR; Duell EJ; Sánchez MJ; Chirlaque MD; Ardanaz E; Larrañaga N; Nodin B; Brändstedt J; Idahl A; Khaw KT; Allen N; Gunter M; Johansson M; Dossus L; Merritt MA; Riboli E; Cramer DW; Kaaks R; Terry KL
    J Ovarian Res; 2017 Mar; 10(1):20. PubMed ID: 28320479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Machine Learning-Enhanced Extraction of Biomarkers for High-Grade Serous Ovarian Cancer from Proteomics Data.
    De Silva S; Alli-Shaik A; Gunaratne J
    Sci Data; 2024 Jun; 11(1):685. PubMed ID: 38918474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
    Fortner RT; Schock H; Le Cornet C; Hüsing A; Vitonis AF; Johnson TS; Fichorova RN; Fashemi T; Yamamoto HS; Tjønneland A; Hansen L; Overvad K; Boutron-Ruault MC; Kvaskoff M; Severi G; Boeing H; Trichopoulou A; Papatesta EM; La Vecchia C; Palli D; Sieri S; Tumino R; Sacerdote C; Mattiello A; Onland-Moret NC; Peeters PH; Bueno-de-Mesquita HBA; Weiderpass E; Quirós JR; Duell EJ; Sánchez MJ; Navarro C; Ardanaz E; Larrañaga N; Nodin B; Jirström K; Idahl A; Lundin E; Khaw KT; Travis RC; Gunter M; Johansson M; Dossus L; Merritt MA; Riboli E; Terry KL; Cramer DW; Kaaks R
    Int J Cancer; 2018 Apr; 142(7):1355-1360. PubMed ID: 29159934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer.
    Cheng Y; Li Q; Sun G; Li T; Zou Y; Ye H; Wang K; Shi J; Wang P
    Sci Rep; 2024 Apr; 14(1):9757. PubMed ID: 38684875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort.
    Terry KL; Schock H; Fortner RT; Hüsing A; Fichorova RN; Yamamoto HS; Vitonis AF; Johnson T; Overvad K; Tjønneland A; Boutron-Ruault MC; Mesrine S; Severi G; Dossus L; Rinaldi S; Boeing H; Benetou V; Lagiou P; Trichopoulou A; Krogh V; Kuhn E; Panico S; Bueno-de-Mesquita HB; Onland-Moret NC; Peeters PH; Gram IT; Weiderpass E; Duell EJ; Sanchez MJ; Ardanaz E; Etxezarreta N; Navarro C; Idahl A; Lundin E; Jirström K; Manjer J; Wareham NJ; Khaw KT; Byrne KS; Travis RC; Gunter MJ; Merritt MA; Riboli E; Cramer DW; Kaaks R
    Clin Cancer Res; 2016 Sep; 22(18):4664-75. PubMed ID: 27060155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Derivation and validation of a nomogram based on clinical characteristics to diagnose endometriosis associated ovarian cancer preoperatively.
    Xu T; Nie X; Zhang L; Meng H; Jiang Y; Wan Y; Cheng W
    J Cancer Res Clin Oncol; 2024 Jan; 150(1):19. PubMed ID: 38243112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovarian Cancer Biomarkers in the COVID-19 Era.
    Farina A; Colaiacovo F; Gianfrate M; Pucci B; Angeloni A; Anastasi E
    Int J Environ Res Public Health; 2023 May; 20(11):. PubMed ID: 37297598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of glutaminase and cancer antigen 125 for distinguishing benign and malignant ovarian tumors.
    Winarno GNA; Effendi JS; Harsono AB; Salima S; Darwizar BD; Sasotya RMS; Rachmawati A; Mulyantari AI; Trianasari N; Handono B
    Clin Transl Sci; 2023 Nov; 16(11):2144-2152. PubMed ID: 37526308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Significance of the TK1-Specific Activity in the Early Detection of Ovarian Cancer.
    Osredkar J; Jagarlamudi KK; Cviič D; Škof E; Cvjetićanin B; Zore A; Lukanović D; Eriksson S; Meglič L
    Oncology; 2024; 102(1):17-29. PubMed ID: 37673047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human epididymis protein 4: Analysis of national health and nutrition examination survey data.
    Penick ER; Beltran TA; Choi YS; Wilson KL
    Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():86-90. PubMed ID: 38598900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.